← back to search

Maike de Wit

Vivantes Klinikum · DE
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lymphoma Diagnosis and Treatment, and Testicular diseases and treatments.
h-index
45
citations
16,695
works
210
NIH funding
primary concept
Medicine
email

Recent publications

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial.
Journal of Clinical Oncology 2025cited by 2position: middledoi
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
The Lancet 2024cited by 102position: middledoi
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Journal of Clinical Oncology 2024cited by 55position: middledoi
Impact of <i>TP53</i> Mutation Status in Elderly <scp>AML</scp> Patients When Adding All‐<i>Trans</i> Retinoic Acid or Valproic Acid to Decitabine
European Journal Of Haematology 2024cited by 6position: middledoi
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma
JAMA Oncology 2024cited by 5position: middledoi
Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype
Clinical Epigenetics 2024cited by 4position: middledoi
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
Journal of Cancer Research and Clinical Oncology 2024cited by 3position: middledoi
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study
Journal of Geriatric Oncology 2024cited by 2position: middledoi
Basic immunization against diphtheria, tetanus and pertussis within the at-risk population of oncological patients: cross-sectional data from the Berlin Metropolitan area
Journal of Public Health 2024cited by 0position: contributordoi
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Journal of Clinical Oncology 2023cited by 135position: middledoi
Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project
Journal of Cancer Research and Clinical Oncology 2023cited by 26position: middledoi
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study
Transfusion Medicine and Hemotherapy 2023cited by 8position: middledoi
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation
Transfusion Medicine and Hemotherapy 2023cited by 6position: middledoi
Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
HemaSphere 2023cited by 3position: middledoi
Activity of decitabine combined with all-&lt;i&gt;trans&lt;/i&gt; retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
Haematologica 2023cited by 2position: middledoi
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Leukemia & lymphoma/Leukemia and lymphoma 2022cited by 55position: middledoi
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial
The Lancet Healthy Longevity 2022cited by 29position: middledoi
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial
Blood 2022cited by 11position: middledoi
Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study.
2022cited by 6position: contributordoi
[Vorwort des DGHO-Vorstandes].
2022cited by 0position: contributordoi
Immunochemotherapy - A Missed Opportunity for Metastasized Malignant Melanoma? Reporting a Therapeutic Success with Checkpoint Inhibitor Rechallenge after Cytotoxic Immuno-Priming in a Heavily Pretreated Patient.
2022cited by 0position: contributordoi
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Journal of Thoracic Oncology 2021cited by 466position: middledoi
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
Journal of Clinical Oncology 2021cited by 100position: middledoi
Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages
Urologia Internationalis 2021cited by 59position: middledoi
Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II – Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy
Urologia Internationalis 2021cited by 33position: middledoi
Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages.
2021cited by 32position: contributordoi
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
Haematologica 2021cited by 21position: middledoi
Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy.
2021cited by 18position: contributordoi
Randomized Phase II Study of All-<i>Trans</i> Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of <i>TP53</i> Status
Blood 2021cited by 3position: middledoi
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
Leukemia 2020cited by 89position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Martin Faehling · Iomedico (Germany)5 papers (2018–2019) · 5 papers (2018–2019) · 5 papers (2018–2019) · 5 papers (2018–2019)Christian Schulz · University of Regensburg4 papers (2018–2019) · 4 papers (2021–2024)Mustafa Özgüroğlu · Istanbul University-Cerrahpaşa3 papers (2019–2021)Axel Benner · Cancer Research And Biostatistics3 papers (2022–2025)Scott Antonia · Parker Institute for Cancer Immunotherapy3 papers (2019–2021)Martin Reck · St. Luke's Clinic3 papers (2018–2021)Carsten Bokemeyer · Eppendorf (Belgium)3 papers (2015–2025)Stefan Angermeier · Klinikum Ludwigsburg3 papers (2022–2024)Ki Hyeong Lee · Korea Environmental Industry and Technology Institute3 papers (2019–2021)David R. Spigel · Henan Cancer Hospital2 papers (2021–2021)Katja Weisel · National Institute Of Blood Disease and Bone Marrow Transplantation2 papers (2022–2025) · 2 papers (2022–2024)David Planchard · Institut Gustave Roussy2 papers (2021–2021)Hans Christian Reinhardt · Düsseldorf University Hospital2 papers (2022–2025)Johannes Betge · German Cancer Research Center2 papers (2022–2024)Annette Dieing · Vivantes Klinikum2 papers (2015–2022)